Immatics Biotechnologies GmbH has received €22 million from its venture capital investors – the final tranche in a Series D round that will enable it to complete a Phase 3 trial of a cancer vaccine for renal cell carcinoma, a type of kidney cancer. ---Subscribe to MedNous to access this article--- Clinical Research Company News Finance, Grants, Deals
